Lab
Clinical Laboratories of Hawaii LLP
Clinical Laboratories of Hawaii LLP was paid $45.76M by Medicaid between Jan 2018 and Dec 2024, across 293 billing codes. Its largest line is 87491, Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe — 5.8% of everything it billed.
33Billing provider infoCLINICAL LABORATORIES OF HAWAII LLP
EWA BEACH, HI 96706
EWA BEACH, HI 96706
33aNPI1134195357assigned 02/27/2006
33bProvider typeClinical Medical Laboratory
28Total paid$45.76M
24GClaims3,350,610
24DCodes billed293
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Hawaii
Rank by total paid#2 of 18
Median peer was paid$163K
This provider vs. median281×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 521,945 | $6.51M | |
| 2019 | 501,772 | $6.24M | |
| 2020 | 410,529 | $5.85M | |
| 2021 | 529,641 | $7.95M | |
| 2022 | 490,678 | $7.08M | |
| 2023 | 467,774 | $6.20M | |
| 2024incomplete | 428,271 | $5.93M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 5.8% | 61,955 | 60,350 | $2.67M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 5.8% | 55,191 | 49,748 | $2.65M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 5.6% | 60,357 | 58,809 | $2.55M |
| 80061 | Lipid panel | 4.8% | 183,061 | 179,841 | $2.18M |
| 80053 | Comprehensive metabolic panel | 4.4% | 217,175 | 205,099 | $2.03M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.4% | 256,989 | 236,446 | $2.01M |
| 84443 | Thyroid stimulating hormone (TSH) | 4.3% | 113,825 | 111,133 | $1.95M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.6% | 35,438 | 31,011 | $1.66M |
| 86003 | 3.6% | 8,444 | 7,955 | $1.63M | |
| 83036 | Hemoglobin; glycosylated (A1C) | 3.0% | 143,221 | 140,623 | $1.36M |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.3% | 39,240 | 38,314 | $1.07M |
| 36415 | Collection of venous blood by venipuncture | 2.0% | 405,462 | 363,003 | $914K |
281 more codes
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.7% | 28,565 | $763K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.5% | 30,877 | $702K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.4% | 17,065 | $628K |
| 80050 | General health panel | 1.3% | 20,435 | $579K |
| 81513 | 1.3% | 5,288 | $573K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.2% | 62,441 | $557K |
| 87077 | 1.0% | 42,287 | $474K | |
| 87186 | <1% | 37,660 | $446K | |
| 86803 | <1% | 26,192 | $432K | |
| 87070 | <1% | 39,696 | $415K | |
| 84702 | <1% | 23,152 | $408K | |
| 82607 | <1% | 25,684 | $389K | |
| 83655 | <1% | 22,441 | $366K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,961 | $359K |
| 84403 | <1% | 12,319 | $353K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 54,910 | $352K |
| 82570 | <1% | 70,815 | $352K | |
| 84439 | <1% | 36,259 | $341K | |
| 82043 | <1% | 59,314 | $322K | |
| 87481 | <1% | 5,278 | $316K | |
| 87480 | <1% | 13,299 | $309K | |
| 87510 | <1% | 13,370 | $298K | |
| 82728 | <1% | 23,387 | $295K | |
| 81001 | <1% | 87,375 | $290K | |
| 82677 | <1% | 9,455 | $283K | |
| 87660 | <1% | 13,298 | $282K | |
| 87340 | <1% | 22,791 | $280K | |
| 84153 | <1% | 15,324 | $279K | |
| 82274 | <1% | 17,902 | $275K | |
| 82105 | <1% | 14,637 | $275K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,602 | $274K |
| 83970 | <1% | 7,775 | $253K | |
| 82670 | <1% | 7,207 | $245K | |
| 84402 | <1% | 7,875 | $229K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 6,604 | $228K |
| 86850 | <1% | 11,081 | $225K | |
| 83550 | <1% | 24,093 | $221K | |
| 82746 | <1% | 13,958 | $201K | |
| 80081 | <1% | 3,850 | $199K | |
| 86038 | <1% | 15,310 | $193K | |
| 86762 | <1% | 9,880 | $187K | |
| 83001 | <1% | 7,834 | $177K | |
| 83540 | <1% | 25,272 | $172K | |
| 86235 | <1% | 2,759 | $168K | |
| 86706 | <1% | 13,131 | $166K | |
| 80074 | <1% | 2,848 | $158K | |
| 86592 | <1% | 29,210 | $157K | |
| 87536 | <1% | 1,811 | $157K | |
| 86787 | <1% | 9,677 | $155K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,570 | $155K |
| 86336 | <1% | 8,915 | $151K | |
| 85027 | <1% | 21,887 | $146K | |
| 87899 | <1% | 7,324 | $144K | |
| 83013 | <1% | 1,896 | $144K | |
| 84146 | <1% | 6,069 | $140K | |
| 86480 | <1% | 2,800 | $139K | |
| 84481 | <1% | 7,258 | $132K | |
| 86704 | <1% | 9,515 | $129K | |
| 87522 | Neg quan hep c or qual rna | <1% | 2,957 | $128K |
| 87529 | <1% | 2,052 | $124K | |
| 86140 | <1% | 20,711 | $119K | |
| 84144 | <1% | 4,702 | $115K | |
| 80076 | <1% | 20,909 | $113K | |
| 83002 | <1% | 5,028 | $112K | |
| 87634 | <1% | 1,543 | $110K | |
| 87653 | <1% | 2,590 | $109K | |
| 85651 | <1% | 29,088 | $107K | |
| 87081 | <1% | 12,229 | $106K | |
| 87075 | <1% | 9,835 | $105K | |
| 87517 | <1% | 2,063 | $99K | |
| 83735 | <1% | 15,064 | $99K | |
| 84550 | <1% | 28,544 | $96K | |
| 83880 | <1% | 4,210 | $96K | |
| 82533 | <1% | 5,202 | $94K | |
| 86160 | <1% | 3,762 | $90K | |
| 85610 | <1% | 23,079 | $89K | |
| 84163 | <1% | 5,094 | $88K | |
| 86901 | <1% | 11,233 | $85K | |
| 82627 | <1% | 3,276 | $84K | |
| 87209 | <1% | 4,544 | $83K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,659 | $75K |
| 82652 | <1% | 1,902 | $74K | |
| 84480 | <1% | 4,958 | $74K | |
| 82785 | <1% | 3,571 | $74K | |
| 84703 | <1% | 7,763 | $73K | |
| 82950 | <1% | 11,922 | $72K | |
| 80069 | <1% | 9,433 | $70K | |
| 86696 | <1% | 2,980 | $68K | |
| 86431 | <1% | 11,627 | $68K | |
| 85018 | <1% | 22,395 | $67K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,428 | $66K |
| 82378 | <1% | 3,487 | $63K | |
| 85730 | <1% | 9,578 | $63K | |
| 83516 | <1% | 3,316 | $62K | |
| 87902 | <1% | 274 | $60K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,530 | $60K |
| 82672 | <1% | 2,265 | $58K | |
| 86039 | <1% | 5,218 | $56K | |
| 86665 | <1% | 1,255 | $56K | |
| 86225 | <1% | 3,653 | $56K | |
| 85014 | <1% | 18,901 | $55K | |
| 83690 | <1% | 7,048 | $54K | |
| 87088 | <1% | 5,829 | $53K | |
| 87045 | <1% | 4,643 | $52K | |
| 87177 | <1% | 4,785 | $50K | |
| 86300 | <1% | 2,977 | $50K | |
| 86376 | <1% | 3,006 | $48K | |
| 86695 | <1% | 2,885 | $46K | |
| 86900 | <1% | 11,242 | $43K | |
| 86800 | <1% | 2,507 | $42K | |
| 87338 | <1% | 3,029 | $42K | |
| 82951 | <1% | 2,744 | $42K | |
| 84156 | <1% | 12,919 | $42K | |
| 86304 | <1% | 1,849 | $41K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 660 | $40K |
| 82784 | <1% | 2,967 | $39K | |
| 87015 | <1% | 5,400 | $39K | |
| 36416 | <1% | 14,372 | $39K | |
| 87046 | <1% | 4,386 | $38K | |
| 87493 | <1% | 917 | $38K | |
| 86708 | <1% | 2,578 | $37K | |
| 83525 | <1% | 2,681 | $36K | |
| 84436 | <1% | 4,713 | $34K | |
| 82248 | <1% | 7,898 | $34K | |
| 86694 | <1% | 1,953 | $34K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 607 | $33K |
| 82247 | <1% | 6,621 | $32K | |
| 84100 | <1% | 9,243 | $31K | |
| 82150 | <1% | 4,320 | $30K | |
| 84460 | <1% | 8,966 | $30K | |
| 82550 | <1% | 6,046 | $29K | |
| 83615 | <1% | 6,226 | $29K | |
| 84270 | <1% | 2,389 | $29K | |
| 83498 | <1% | 861 | $29K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,742 | $27K |
| 87205 | <1% | 6,149 | $27K | |
| 82565 | <1% | 7,272 | $26K | |
| 86677 | <1% | 1,563 | $26K | |
| 86735 | <1% | 1,487 | $24K | |
| 84450 | <1% | 7,730 | $24K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 2,867 | $24K |
| 86765 | <1% | 1,477 | $24K | |
| 81003 | <1% | 9,637 | $23K | |
| 86200 | <1% | 1,890 | $22K | |
| 86360 | <1% | 420 | $22K | |
| 84425 | <1% | 1,019 | $22K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 44 | $21K |
| 82977 | <1% | 3,502 | $21K | |
| 87040 | <1% | 1,404 | $20K | |
| 83090 | <1% | 1,305 | $20K | |
| 84165 | <1% | 2,472 | $20K | |
| 86364 | <1% | 1,559 | $19K | |
| 84479 | <1% | 2,834 | $19K | |
| 86359 | <1% | 445 | $18K | |
| 82024 | <1% | 506 | $18K | |
| 80055 | <1% | 938 | $18K | |
| 80164 | <1% | 1,482 | $18K | |
| 82947 | <1% | 5,032 | $18K | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 5,061 | $18K |
| 81229 | <1% | 42 | $17K | |
| 83014 | <1% | 1,894 | $17K | |
| 83020 | <1% | 1,166 | $17K | |
| 83883 | <1% | 833 | $16K | |
| 80177 | <1% | 1,645 | $16K | |
| 83721 | <1% | 1,695 | $15K | |
| 84484 | <1% | 1,517 | $15K | |
| 82465 | <1% | 3,810 | $15K | |
| 82310 | <1% | 3,816 | $14K | |
| 81015 | <1% | 4,511 | $14K | |
| 86663 | <1% | 838 | $14K | |
| 86664 | <1% | 710 | $14K | |
| 84154 | <1% | 884 | $13K | |
| 82952 | <1% | 2,703 | $13K | |
| 87076 | <1% | 996 | $13K | |
| 86334 | <1% | 777 | $13K | |
| 84520 | <1% | 5,077 | $13K | |
| 84305 | <1% | 501 | $12K | |
| 84681 | <1% | 502 | $12K | |
| 85045 | <1% | 2,810 | $12K | |
| 86060 | <1% | 1,308 | $11K | |
| 80197 | <1% | 672 | $11K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 87 | $11K |
| 86777 | <1% | 528 | $10K | |
| 83521 | <1% | 625 | $10K | |
| 87563 | <1% | 321 | $10K | |
| 85379 | <1% | 874 | $10K | |
| 85007 | <1% | 2,443 | $10K | |
| 84445 | <1% | 286 | $9K | |
| 83520 | <1% | 579 | $9K | |
| 82140 | <1% | 602 | $9K | |
| 84630 | <1% | 705 | $9K | |
| 86778 | <1% | 436 | $8K | |
| 83993 | <1% | 361 | $8K | |
| 83825 | <1% | 416 | $7K | |
| 80178 | <1% | 990 | $7K | |
| 86147 | <1% | 82 | $6K | |
| 87329 | <1% | 477 | $6K | |
| 82525 | <1% | 436 | $6K | |
| 83921 | <1% | 387 | $6K | |
| 87106 | <1% | 541 | $6K | |
| 82175 | <1% | 295 | $6K | |
| 86141 | <1% | 1,417 | $6K | |
| 84134 | <1% | 449 | $5K | |
| 84482 | <1% | 361 | $5K | |
| 87449 | <1% | 428 | $5K | |
| 87324 | <1% | 418 | $5K | |
| 86258 | <1% | 348 | $5K | |
| 84478 | <1% | 934 | $5K | |
| 87350 | <1% | 310 | $5K | |
| 86769 | <1% | 636 | $4K | |
| 86308 | <1% | 598 | $4K | |
| 82610 | <1% | 265 | $4K | |
| 84207 | <1% | 169 | $4K | |
| 84704 | <1% | 198 | $4K | |
| 86870 | <1% | 124 | $4K | |
| 86709 | <1% | 274 | $4K | |
| 87625 | <1% | 97 | $3K | |
| 86593 | <1% | 604 | $3K | |
| 84132 | <1% | 894 | $3K | |
| 82397 | <1% | 220 | $3K | |
| 80051 | <1% | 431 | $3K | |
| 84432 | <1% | 158 | $3K | |
| 86301 | <1% | 144 | $2K | |
| 87252 | <1% | 71 | $2K | |
| 86146 | <1% | 27 | $2K | |
| 87420 | <1% | 121 | $2K | |
| 85613 | <1% | 150 | $2K | |
| 86707 | <1% | 128 | $2K | |
| 87581 | <1% | 44 | $2K | |
| 87486 | <1% | 44 | $2K | |
| 82390 | <1% | 121 | $1K | |
| 80185 | <1% | 137 | $1K | |
| 87102 | <1% | 142 | $1K | |
| 87185 | <1% | 425 | $1K | |
| 80361 | <1% | 51 | $1K | |
| 83010 | <1% | 89 | $1K | |
| 80349 | <1% | 68 | $1K | |
| 85060 | <1% | 89 | $1K | |
| 83718 | <1% | 106 | $971.39 | |
| 80156 | <1% | 57 | $930.52 | |
| 87254 | <1% | 53 | $924.49 | |
| 87116 | <1% | 107 | $876.97 | |
| 86381 | <1% | 40 | $834.39 | |
| 0099U | <1% | 20 | $773.83 | |
| 82166 | <1% | 28 | $764.69 | |
| 82330 | <1% | 62 | $709.76 | |
| 87497 | <1% | 13 | $700.30 | |
| 87799 | <1% | 17 | $694.49 | |
| 87210 | <1% | 125 | $673.92 | |
| 87535 | <1% | 17 | $655.16 | |
| 82679 | <1% | 25 | $637.22 | |
| 86361 | <1% | 39 | $626.72 | |
| 87181 | <1% | 228 | $618.84 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 73 | $612.66 |
| 86705 | <1% | 38 | $546.69 | |
| 80162 | <1% | 55 | $544.82 | |
| 82103 | <1% | 38 | $536.67 | |
| 84075 | <1% | 169 | $508.72 | |
| 86162 | <1% | 28 | $453.44 | |
| 82040 | <1% | 204 | $445.52 | |
| 84255 | <1% | 13 | $421.29 | |
| 86355 | <1% | 12 | $420.55 | |
| 87206 | <1% | 93 | $392.15 | |
| 83519 | <1% | 26 | $382.06 | |
| 86335 | <1% | 17 | $351.44 | |
| 80324 | <1% | 17 | $347.08 | |
| 82542 | <1% | 14 | $301.67 | |
| 86645 | <1% | 12 | $279.21 | |
| 82172 | <1% | 67 | $273.36 | |
| 82232 | <1% | 13 | $226.47 | |
| 86255 | <1% | 16 | $204.23 | |
| 84466 | <1% | 12 | $193.31 | |
| 85660 | <1% | 27 | $187.74 | |
| 84300 | <1% | 40 | $187.22 | |
| 87253 | <1% | 14 | $186.75 | |
| 80184 | <1% | 12 | $167.21 | |
| 81050 | <1% | 56 | $149.68 | |
| 82575 | <1% | 14 | $143.56 | |
| 80175 | <1% | 13 | $113.75 | |
| 83695 | <1% | 35 | $90.56 | |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | <1% | 403 | $85.21 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPARK, ALYSSA (CEO)
| Provider | Location | Paid |
|---|---|---|
| Pan Pacific Pathologists, LLC | Ewa Beach, HI | $4.00M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.